Sanofi India Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 5 Aug 2026

Company page: Sanofi India share price, financials & guidance record

Sanofi India delivered a strong Q2 FY27, primarily driven by robust double-digit growth in its diabetes portfolio and effective cost management, leading to significant PBT and margin expansion. However, the partnership and export businesses faced headwinds, impacting overall H1 performance. The company remains focused on leveraging its existing diabetes portfolio and optimizing resources, while addressing competitive pressures in certain segments.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 7.9%, net profit up 20.0% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	524	515	536	406	475 −9%	420 −18%	472 −12%	438 +8%
Expenses	404	397	364	311	341	330	330	322
EBITDA	120	118	172	95	134 +12%	90 −24%	143 −17%	115 +21%
Margin	23%	23%	32%	23%	28%	22%	30%	26%
Other income	2	14	3	9	-22	3	4	6
Interest	0	0	0	0	0	1	0	0
Depreciation	9	10	10	9	9	10	9	9
Profit before tax	113	122	165	94	102 −10%	83 −32%	138 −16%	112 +19%
Tax rate	27%	25%	28%	26%	26%	26%	26%	26%
Net profit	82	91	120	70	76 −7%	62 −32%	103 −14%	84 +20%
EPS	35.74	39.70	51.96	30.22	33.04	26.83	44.61	36.30

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls